BioFlo 44012Recalls & reported problems
Navilyst Medical, Inc. · BioFlo Plastic Port with Filled Suture Holes and 6F x 63cm Polyurethane Catheter with ENDEXO Technology · Class 2 · Implant
All models of BioFlo (87)
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 1
- Deaths reported
- 0
- Injuries reported
- 0
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI H965440120), received between Dec 19, 2023 and Dec 19, 2023 — classified as 1 malfunction.
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Reports received per month
Most reported problems
Device problems
- Adverse Event Without Identified Device or Use Problem1
Patient problems
- Implant Pain1
- Pain1
Recent adverse event reports
The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.
MalfunctionDec 19, 2023Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
ANGIODYNAMICS RECEIVED A USER MEDWATCH (B)(4). A RISK MANAGER REPORTED AN ISSUE WITH A BIOFLO 6F SINGLE PLASTIC FILLED; NON-VALVED. THE FOLLOWING WAS REPORTED: "PATIENT IN CLINIC RECEIVING CHEMOTHERAPY. IMPLANTED PORT-A-CATH (PAC) LOWER RIGHT CHEST LATERAL TO ARMPIT ACCESSED WITH 20-GAUGE 3/4-INCH HUBER NEEDLE, SKIN INTACT; PORT ACCESSED PER PROTOCOL USING ASEPTIC TECHNIQUE, BRISK BLOOD RETURNED ACHIEVED AFTER 2ND RN ASSESSED PLACEMENT AND FLUSH PERFORMED WITHOUT DISCOMFORT, EASILY WITH BRISK BLOOD RETURN. PATIENT IS ABLE TO TASTE SALINE, NEEDLE SECURED WITH TEGADERM DRESSING. KVO FLUIDS INITIATED VIA PAC AND PRE-MEDS ADMINISTERED. PREMEDS GIVEN PER MAR. CHEMOTHERAPY ADMINISTERED SUBSEQUENTLY PER ORDERS; OXALIPLATIN AND LEUCOVORIN ADMINISTERED CONCURRENTLY PER PROTOCOL. PATIENT TOLERATED INFUSION WITHOUT ANY ADVERSE SIDE EFFECTS. POST OXALIPLATIN AND LEUKOVORIN, PATIENT NOTED THAT 'PORT' WAS 'HURTING'. PORT ASSESSED, NO VISIBLE SIGNS OF INFECTION, PORT FLUSHES EASILY, PATIENT ABLE TO TASTE/SMELL, NO BLOOD RETURN NOTED ON FLUSH. ON FURTHER REASSESSMENT AND REMOVAL OF TEGADERM, PATIENT STATES TENDERNESS ABOVE RIGHT BREAST WITHOUT REDNESS, STREAKING OR WARMTH. TREATMENT DISCONTINUED,
Patient problems: Implant Pain; Pain
MAUDE report 18357653 ↗
Other PORT & CATHETER, IMPLANTED, SUBCUTANEOUS, INTRAVASCULAR devices
- PowerPort M.R.I., Groshong 9808560Bard Access Systems, Inc. · PORT & CATHETER, IMPLANTED, SUBCUTANEOUS, INTRAVASCULAR3 deaths834 reports
- PowerPort ClearVUE 1608062Bard Access Systems, Inc. · PORT & CATHETER, IMPLANTED, SUBCUTANEOUS, INTRAVASCULAR18 deaths571 reports
- PowerPort ClearVUE 5608062Bard Access Systems, Inc. · PORT & CATHETER, IMPLANTED, SUBCUTANEOUS, INTRAVASCULAR31 deaths542 reports
- PowerPort M.R.I., ChronoFlex 1808000Bard Access Systems, Inc. · PORT & CATHETER, IMPLANTED, SUBCUTANEOUS, INTRAVASCULAR19 deaths513 reports
- PowerPort M.R.I., ChronoFlex 1808060Bard Access Systems, Inc. · PORT & CATHETER, IMPLANTED, SUBCUTANEOUS, INTRAVASCULAR1 recall15 deaths383 reports
- PowerPort M.R.I., Groshong 1808560Bard Access Systems, Inc. · PORT & CATHETER, IMPLANTED, SUBCUTANEOUS, INTRAVASCULAR10 deaths304 reports
- PowerPort M.R.I., ChronoFlex 1829500Bard Access Systems, Inc. · PORT & CATHETER, IMPLANTED, SUBCUTANEOUS, INTRAVASCULAR6 deaths197 reports
- BardPort M.R.I. 0602680Bard Access Systems, Inc. · PORT & CATHETER, IMPLANTED, SUBCUTANEOUS, INTRAVASCULAR2 deaths179 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page